Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy forEGFR-mutated Non-small Cell Lung Cancer

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics

“…Amivantamab is a bispecific EGFR/MET antibody that received FDA accelerated approval for EGFR exon 20 insertion mutated NSCLC, and the ongoing CHRYSALIS trial explores its use in MET dysregulated NSCLC in both MET ex14 and post-EGFR-TKI MET amplified cohorts. 71 Emibetuzumab is a bivalent MET/MET antibody that, when added to first-line erlotinib, increases ORR from 66% to 85% in EGFR-mutated NSCLC. 72 Another bivalent MET/MET antibody, REGN5093, is currently being studied in a first-in-human phase I/II trial for MET ex14 or MET amplified NSCLC.…”

The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer

“…Several small-molecule EGFR inhibitors have gained Food and Drug Administration (FDA) approval for the treatment of lung cancer, including gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, and mobocertinib. Anti-EGFR monoclonal antibodies such as amivantamab-vmjw have also been approved for the treatment of lung cancer patients who possess unique mutations that are not as susceptible to treatment with TKIs, such as exon 20 insertions [4]. Despite these breakthrough drugs, current recommendations confine the utilization of TKIs as first-line therapies to patients possessing a relatively narrow subset of mutations.…”